Freund Corporation (TYO:6312)

Verve Therapeutics Balance Sheet

Financials in millions JPY. Fiscal year is March - February.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2025	Feb 28, 2025	Feb 29, 2024	Feb 28, 2023	Feb 28, 2022	Feb 28, 2021
Cash & Equivalents	4,428	5,152	4,736	3,917	4,145	4,498
Short-Term Investments	-	-	-	-	-	212
Cash & Short-Term Investments	4,428	5,152	4,736	3,917	4,145	4,710
Cash Growth	-3.80%	8.78%	20.91%	-5.50%	-12.00%	9.18%
Receivables	5,385	6,192	7,009	5,520	5,216	4,860
Inventory	8,211	7,515	5,815	5,586	5,090	3,473
Prepaid Expenses	307	290	221	199	211	151
Other Current Assets	540	499	756	648	342	364
Total Current Assets	18,871	19,648	18,537	15,870	15,004	13,558
Property, Plant & Equipment	4,085	4,182	4,455	4,441	4,562	4,734
Long-Term Investments	1,285	1,303	1,142	1,113	1,036	803
Goodwill	-	-	-	-	643	1,089
Other Intangible Assets	844	888	1,150	967	791	100
Long-Term Deferred Tax Assets	536	536	503	366	235	214
Other Long-Term Assets	2	2	2	1	2	1
Total Assets	25,623	26,559	25,789	22,758	22,273	20,499
Accounts Payable	2,932	3,105	3,882	2,730	2,743	2,966
Accrued Expenses	380	883	798	672	622	680
Short-Term Debt	85	108	515	896	-	55
Current Income Taxes Payable	220	341	330	130	256	245
Other Current Liabilities	6,185	5,974	4,395	3,387	3,414	1,871
Total Current Liabilities	9,802	10,411	9,920	7,815	7,035	5,817
Long-Term Leases	331	352	380	408	376	394
Other Long-Term Liabilities	139	145	154	140	185	101
Total Liabilities	10,485	11,123	10,766	8,642	7,918	6,615
Common Stock	1,035	1,035	1,035	1,035	1,035	1,035
Additional Paid-In Capital	1,340	1,332	1,289	1,289	1,289	1,289
Retained Earnings	12,460	12,587	12,287	11,899	12,808	12,625
Treasury Stock	-695	-693	-701	-773	-773	-773
Comprehensive Income & Other	998	1,175	1,113	666	-4	-292
Total Common Equity	15,138	15,436	15,023	14,116	14,355	13,884
Shareholders' Equity	15,138	15,436	15,023	14,116	14,355	13,884
Total Liabilities & Equity	25,623	26,559	25,789	22,758	22,273	20,499
Total Debt	416	460	895	1,304	376	449
Net Cash (Debt)	4,012	4,692	3,841	2,613	3,769	4,261
Net Cash Growth	5.16%	22.16%	47.00%	-30.67%	-11.55%	-0.49%
Net Cash Per Share	237.22	277.49	228.25	156.06	225.10	254.48
Filing Date Shares Outstanding	16.91	16.92	16.9	16.74	16.74	16.74
Total Common Shares Outstanding	16.91	16.92	16.9	16.74	16.74	16.74
Working Capital	9,069	9,237	8,617	8,055	7,969	7,741
Book Value Per Share	895.27	912.50	889.00	843.02	857.30	829.17
Tangible Book Value	14,294	14,548	13,873	13,149	12,921	12,695
Tangible Book Value Per Share	845.35	860.00	820.95	785.27	771.66	758.16
Order Backlog	-	17,076	15,843	12,827	10,574	6,616

Updated Jan 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.